Twenty-four-hour effects of bimatoprost 0.01% monotherapy on intraocular pressure and ocular perfusion pressure

BMJ Open

Volumn 2, Issue 4, 2012, Pages

  Tung, Jonathan D ^a   Tafreshi, Ali ^a   Weinreb, Robert N ^a   Slight, J Rigby ^a   Medeiros, Felipe A ^a   Liu, John H K ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIMATOPROST; DORZOLAMIDE; LATANOPROST;

ADULT; AGED; ARTICLE; BEDTIME DOSAGE; BODY POSITION; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG EFFECT; FEMALE; HUMAN; INTRAOCULAR HYPERTENSION; INTRAOCULAR PRESSURE; MALE; MONOTHERAPY; OCULAR PERFUSION PRESSURE; OPEN ANGLE GLAUCOMA; VISUAL SYSTEM PARAMETERS;

EID: 84865956656     PISSN: None     EISSN: 20446055     Source Type: Journal    
DOI: 10.1136/bmjopen-2012-001106     Document Type: Article

References (26)

1. Weinreb RN, Khaw PT. Primary open-angle glaucoma. Lancet 2004;363:1711-20. (Pubitemid 38670330)
2. Weinreb RN, Harris A. Ocular blood flow in Glaucoma. WGA consensus series 6. Amsterdam, the Netherlands: Kugler Publications, 2009:59-128.
3. Medeiros FA, Brandt J, Liu J, et al. IOP as a risk factor for glaucoma development and progression. In: Weinreb RN, Brandt JD, Garway-Heath DF, et al. Intraocular pressure: reports and consensus statements of the 4th Global AIGS Consensus meeting on intraocular pressure. The Hague, The Netherlands: Kugler, 2007:59-74. WGA Consensus Series 4.
4. Bagga H, Liu JH, Weinreb RN. Intraocular pressure measurements throughout the 24 h. Curr Opin Ophthalmol 2009;20:79-83.
5. Orzalesi N, Rossetti L, Invernizzi T, et al. Effect of timolol, latanoprost, and dorzolamide on circadian IOP in glaucoma or ocular hypertension. Invest Ophthalmol Vis Sci 2000;41:2566-73. (Pubitemid 30624384)
6. Liu JH, Kripke DF, Weinreb RN. Comparison of the nocturnal effects of once-daily timolol and latanoprost on intraocular pressure. Am J Ophthalmol 2004;138:389-95. (Pubitemid 39208565)
7. Sit AJ, Weinreb RN, Crowston JG, et al. Sustained effect of travoprost on diurnal and nocturnal intraocular pressure. Am J Ophthalmol 2006;141:1131-3. (Pubitemid 43831052)
8. Liu JH, Medeiros FA, Slight JR, et al. Comparing diurnal and nocturnal effects of brinzolamide and timolol on intraocular pressure in patients receiving latanoprost monotherapy. Ophthalmology 2009;116:449-54.
9. Liu JH, Medeiros FA, Slight JR, et al. Diurnal and nocturnal effects of brimonidine monotherapy on intraocular pressure. Ophthalmology 2010;117:2075-9.
10. Woodward DF, Phelps RL, Krauss AH, et al. Bimatoprost: a novel antiglaucoma agent. Cardiovasc Drug Rev 2004;22:103-20. (Pubitemid 38879875)
11. Toris CB, Gabelt BT, Kaufman PL. Update on the mechanism of action of topical prostaglandins for intraocular pressure reduction. Surv Ophthalmol 2008;53(Suppl 1):S107-20.
12. Williams RD, Cohen JS, Gross RL, et al. Long-term efficacy and safety of bimatoprost for intraocular pressure lowering in glaucoma and ocular hypertension: year 4. Br J Ophthalmol 2008;92:1387-92.
13. Aptel F, Cucherat M, Denis P. Efficacy and tolerability of prostaglandin analogs: a meta-analysis of randomized controlled clinical trials. J Glaucoma 2008;17:667-73.
14. Konstas AG, Katsimbris JM, Lallos N, et al. Latanoprost 0.005% versus bimatoprost 0.03% in primary open-angle glaucoma patients. Ophthalmology 2005;112:262-6. (Pubitemid 40202562)
15. Katz LJ, Cohen JS, Batoosingh AL, et al. Twelve-month, randomized, controlled trial of bimatoprost 0.01%, 0.0125%, and 0.03% in patients with glaucoma or ocular hypertension. Am J Ophthalmol 2010;149:661-71 e1.
16. Liu JH, Zhang X, Kripke DF, et al. Twenty-four-hour intraocular pressure pattern associated with early glaucomatous changes. Invest Ophthalmol Vis Sci 2003;44:1586-90. (Pubitemid 36378585)
17. Liu JH, Kripke DF, Twa MD, et al. Twenty-four-hour pattern of intraocular pressure in the aging population. Invest Ophthalmol Vis Sci 1999;40:2912-7. (Pubitemid 29521605)
18. Mansouri K, Shaarawy T. Continuous intraocular pressure monitoring with a wireless ocular telemetry sensor: initial clinical experience in patients with open angle glaucoma. Br J Ophthalmol 2011;95:627-9.
19. Liu JH, Weinreb RN. Monitoring intraocular pressure for 24 h. Br J Ophthalmol 2011;95:599-600.
20. Liu JH, Gokhale PA, Loving RT, et al. Laboratory assessment of diurnal and nocturnal ocular perfusion pressures in humans. J Ocul Pharmacol Ther 2003;19:291-7. (Pubitemid 37013003)
21. Quaranta L, Gandolfo F, Turano R, et al. Effects of topical hypotensive drugs on circadian IOP, blood pressure, and calculated diastolic ocular perfusion pressure in patients with glaucoma. Invest Ophthalmol Vis Sci 2006;47:2917-23. (Pubitemid 351639767)
22. Nakamura T, Yamada M, Teshima M, et al. Electrophysiological characterization of tight junctional pathway of rabbit cornea treated with ophthalmic ingredients. Biol Pharm Bull 2007;30:2360-4. (Pubitemid 350223743)
23. Orzalesi N, Rossetti L, Bottoli A, et al. Comparison of the effects of latanoprost, travoprost, and bimatoprost on circadian intraocular pressure in patients with glaucoma or ocular hypertension. Ophthalmology 2006;113:239-46. (Pubitemid 43170772)
24. Yildirim N, Sahin A, Gultekin S. The effect of latanoprost, bimatoprost, and travoprost on circadian variation of intraocular pressure in patients with open-angle glaucoma. J Glaucoma 2008;17:36-9. (Pubitemid 351321474)
25. Quaranta L, Pizzolante T, Riva I, et al. Twenty-four-hour intraocular pressure and blood pressure levels with bimatoprost versus latanoprost in patients with normal-tension glaucoma. Br J Ophthalmol 2008;92:1227-31.
26. Konstas AG, Hollo G, Mikropoulos D, et al. Twenty-four-hour intraocular pressure control with bimatoprost and the bimatoprost/timolol fixed combination administered in the morning, or evening in exfoliative glaucoma. Br J Ophthalmol 2010;94:209-13.